Beneficial effect of treatment with transdermal estradiol-17-β on exercise-induced angina and ST segment depression in syndrome X

doi:10.1016/0167-5273(96)02560-0

International Journal of Cardiology

Volume 54, Issue 1, 19 April 1996, Pages 13-20

https://doi.org/10.1016/0167-5273(96)02560-0 Get rights and content

Abstract

We investigated the acute effect of transdermal estradiol-17-β on exercise-induced ischemia in 15 postmenopausal women (mean age 58 ± 6 years) with syndrome X (angina pectoris, positive exercise test and normal coronary angiogram) and eight healthy women (mean age 58 ± 5 years) in a placebo-controlled, double-blind crossover trial. Two exercise tests were performed on separate days, separated by at least 1 week, after application of placebo or 100 μg/24 h estradiol-17-β. In the control group there was no difference between estradiol and placebo. Patients with syndrome X, on the other hand, showed an increased time to angina (323 ± 99 versus 233 ± 67 s, P = 0.0044), time to 1 mm ST depression (257 ± 142 versus 187 ± 122s, P = 0.039), total exercise time (363 ± 104 versus 323 ± 85 s, P = 0.038), and working capacity (93 ± 17 versus 89 ± 15W, P = 0.0086) during active treatment. In conclusion, estradiol-17-β has a beneficial effect on myocardial ischemia in postmenopausal women with syndrome X and may be a useful therapeutic agent in this disease.

References (35)

HG Kemp et al.
Seven year survival of patients with normal or near normal coronary arteriograms: a CASS registry study
J Am Coll Cardiol
(1986)
V Legrand et al.
Abnormal coronary flow reserve and abnormal radionucleide exercise test in patients with normal coronary angiograms
J Am Coll Cardiol
(1985)
MA Greenberg et al.
Impaired coronary vasodilator responsiveness as a cause of lactate production during pacing-induced ischemia in patients with angina pectoris and normal coronary arteries
J Am Coll Cardiol
(1987)
F Romeo et al.
Long-term follow up of patients initially diagnosed with syndrome X
Am J Cardiol
(1993)
MK Hong et al.
Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women
Am J Cardiol
(1992)
JK Williams et al.
Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries
J Am Coll Cardiol
(1992)
GM Rosano et al.
Beneficial effect of oestrogen on exercise-induced myocardial ischemia in women with coronary artery disease
Lancet
(1993)
PM Sarrel et al.
Angina and normal coronary arteries in women: Gynaecologic findings
Am J Obstet Gynecol
(1992)
JS Mogil et al.
Sex differences in the antagonism of swimstress-induced analgesia: effects of gonadectomy and estrogen replacement
Pain
(1993)
P Vaitkevicius et al.
Effect of estrogen replacement therapy on the ST-segment response to postural and hyperventilation stimuli
Am J Cardiol
(1989)

A Marmor et al.

Effects of bilateral hysterosalpingo-oophorectomy on exercise-induced ST-segment abnormalities in young women

Am J Cardiol

(1993)

PM Sarrel

Ovarian hormones and the circulation

Maturitas

(1990)

RE Glendy et al.

Coronary disease in youth: comparison of 100 patients under 40 with 300 persons past 80

JAMA

(1930)

HG Kemp et al.

The anginal syndrome with normal coronary arteriography

Trans Ass Am Phys

(1967)

G Rosano et al.

Syndrome X in women: the importance of ovarian hormones

J Am Cell Cardiol

(1992)

D Opherk et al.

Reduced coronary dilatory capacity and ultrastructural changes of the myocardium in patients with angina pectoris but normal coronary arteriograms

Circulation

(1981)

RO Cannon et al.

Left ventricular dysfunction in patients with angina pectoris, normal epicardial coronary arteries, and abnormal vasodilator reserve

Circulation

(1985)

Cited by (44)

Pharmacologic Treatment of Patients With Myocardial Ischemia With No Obstructive Coronary Artery Disease
2018, American Journal of Cardiology
Citation Excerpt :
Ranolazine27 and nicorandil44 each significantly improved outcomes in a single trial. Hormone therapy improved EST outcomes in only 1 of 4 trials.37–40 Nitrates,20–22 ivabradine,27 and trimetazidine15 did not improve EST outcomes.
Half of women and 1/3 of men with angina and ischemia on stress testing have ischemia with no obstructive coronary artery disease (INOCA). These patients have quality of life (QoL) impairment comparable with patients with obstructive coronary artery disease. Clinicians generally treat INOCA with traditional antianginal agents despite previous studies demonstrating variable response to these medications. We performed a systematic review to evaluate the efficacy and safety of available pharmacologic therapies for INOCA. We systematically searched the Cochrane Central Register of Controlled Trials, Embase, MEDLINE, and the World Health Organization International Clinical Trials Registry Platform in July 2017 for randomized controlled trials (RCTs) evaluating pharmacologic agents for INOCA. The primary outcome of interest was QoL. Secondary outcomes included subjective and objective efficacy measures and safety outcomes. We included 35 RCTs from 333 identified studies. Interventions that improved QoL with moderate-quality evidence included angiotensin-converting enzyme (ACE) inhibitor (±statin) and ranolazine. Low-to-very-low-quality evidence also suggests that ACE inhibitors, β blockers, calcium-channel blockers, nicorandil, ranolazine, and statins may decrease angina frequency and delay ischemia on stress testing. Other interventions, most notably nitrates, did not significantly improve any outcome. In conclusion, evidence for pharmacologic treatment of INOCA is generally poor, and higher-quality RCTs using a standardized definition of INOCA are needed. Moderate-quality evidence suggests that ACE inhibitors and ranolazine improve QoL. Other interventions had low-quality evidence or no evidence of efficacy.
Cardiac syndrome X: Current concepts
2010, International Journal of Cardiology
Cardiac syndrome X is a heterogeneous entity, both clinically and pathophysiologically, encompassing a variety of pathogenic mechanisms. Management of this syndrome represents a major challenge to the treating physician. They often seek medical care because of recurring and disabling chest pain, which may imply repetitive and costly invasive and non-invasive investigations. A careful patient evaluation for underlying pathophysiologic mechanism and exclusion of other causes of chest pain along with attention to various psychological aspects is helpful in reducing the stress and suffering of these patients. This article reviews the available literature on the pathophysiology and current controversies surrounding the management of this difficult to treat condition.
A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: Results from the National Institutes of Health/National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE)
2010, American Heart Journal
Citation Excerpt :
These findings confirm and extend prior published trial reports in women with chest pain, abnormal stress testing result, and no obstructive CAD.19 Previous study has suggested that estrogen hormone therapy is associated with improved exercise-induced angina and exercise capacity.20 Although our data suggest a trend for improved exercise stress testing parameters at exit for the1/10 NA/EE group, the absence of statistical significance may be due to low statistical power, precluding a definitive result.
Compared with men, women have more evidence of myocardial ischemia with no obstructive coronary artery disease. Although low endogenous estrogen levels are associated with endothelial dysfunction, the role of low-dose hormone therapy has not been fully evaluated. We postulate that a 12-week duration of low-dose hormone replacement therapy is associated with myocardial ischemia and endothelial dysfunction.
Using a multicenter, randomized, placebo-controlled design, subjects were randomized to receive either 1 mg norethindrone/10 μg ethinyl estradiol or placebo for 12 weeks. Chest pain and menopausal symptoms, cardiac magnetic resonance spectroscopy, brachial artery reactivity, exercise stress testing, and psychosocial questionnaires were evaluated at baseline and exit. Recruitment was closed prematurely because of failure to recruit after publication of the Women's Health Initiative hormone trial. Of the 35 women who completed the study, there was less frequent chest pain in the treatment group compared with the placebo group (P = .02) at exit. Women taking 1 mg norethindrone/10 μg ethinyl estradiol also had significantly fewer hot flashes/night sweats (P = .003), less avoidance of intimacy (P = .05), and borderline differences in sexual desire and vaginal dryness (P = .06). There were no differences in magnetic resonance spectroscopy, brachial artery reactivity, compliance, or reported adverse events between the groups.
These data suggest that low-dose hormone therapy improved chest pain symptoms, menopausal symptoms, and quality of life, but did not improve ischemia or endothelial dysfunction. Given that it was not possible to enroll the prespecified sample size, these results should not be considered definitive.
The Pathophysiology and Clinical Course of the Normal Coronary Angina Syndrome (Cardiac Syndrome X)
2008, Progress in Cardiovascular Diseases
Citation Excerpt :
However, in line with all other treatments for syndrome X, the results from a host of different replacement regimens including transdermal estrogen, conjugated equine estrogens, as well as various combinations of estrogen and progesterone have been variable.54 Some studies have demonstrated an excellent clinical response, whereas others have found no improvement in symptoms and/or markers of ischemia during stress testing.52,54,94,103,104 Furthermore, there is some evidence that the acute/short-term beneficial effects of estrogen may not be sustained in the long term.54,104
Cardiac Syndrome X and Endothelial Dysfunction: New Concepts in Prognosis and Treatment
2006, American Journal of Medicine
Cardiac syndrome X (CSX), or angina with no flow-limiting stenosis on coronary angiogram, has been regarded as a condition with an excellent prognosis despite variable symptomatic improvement. Newer data show that patients with CSX with endothelial dysfunction have an increased risk for future adverse cardiac events. Current hypotheses of CSX pathophysiology emphasize a dysfunctional vascular endothelium that leads to microvascular ischemia. Treatments that target improving endothelial function, such as statins, angiotensin-converting enzyme inhibitors, estrogen, and lifestyle modification, are promising additions to treatment regimens for CSX. The goal of this article is to provide information for improved diagnosis, risk stratification, and therapy for the population with CSX.
Updates on Pharmacologic Management of Microvascular Angina
2022, Cardiovascular Therapeutics

View all citing articles on Scopus

View full text

Original studyBeneficial effect of treatment with transdermal estradiol-17-β on exercise-induced angina and ST segment depression in syndrome X

Abstract

J Am Coll Cardiol

J Am Coll Cardiol

J Am Coll Cardiol

Am J Cardiol

Am J Cardiol

J Am Coll Cardiol

Lancet

Am J Obstet Gynecol

Pain

Am J Cardiol

Am J Cardiol

Maturitas

Coronary disease in youth: comparison of 100 patients under 40 with 300 persons past 80

JAMA

The anginal syndrome with normal coronary arteriography

Trans Ass Am Phys

Syndrome X in women: the importance of ovarian hormones

J Am Cell Cardiol

Reduced coronary dilatory capacity and ultrastructural changes of the myocardium in patients with angina pectoris but normal coronary arteriograms

Circulation

Left ventricular dysfunction in patients with angina pectoris, normal epicardial coronary arteries, and abnormal vasodilator reserve

Circulation

Original study
Beneficial effect of treatment with transdermal estradiol-17-β on exercise-induced angina and ST segment depression in syndrome X